Pharvaris (NASDAQ:PHVS) President Sells $3,500,000.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 100,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total transaction of $3,500,000.00. Following the completion of the transaction, the president directly owned 64,953 shares of the company’s stock, valued at $2,273,355. The trade was a 60.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Peng Lu also recently made the following trade(s):

• On Friday, September 11th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $40.13, for a total transaction of $601,950.00.
• On Tuesday, September 8th, Peng Lu sold 15,000 shares of Pharvaris stock. The shares were sold at an average price of $40.68, for a total transaction of $610,200.00.

Pharvaris Trading Down 1.0%

Shares of NASDAQ:PHVS traded down $0.35 on Monday, hitting $36.02. 653,689 shares of the company were exchanged, compared to its average volume of 412,750. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25. The stock’s 50 day moving average price is $35.37 and its 200 day moving average price is $31.75. The firm has a market capitalization of $2.36 billion, a P/E ratio of -11.81 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities analysts predict that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PHVS. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, September 9th. Wedbush upped their target price on Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Leerink Partners increased their price target on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Oppenheimer reissued an “outperform” rating and set a $75.00 price target on shares of Pharvaris in a research report on Tuesday, September 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $59.87.

Hedge Funds Weigh In On Pharvaris

Large investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. boosted its stake in shares of Pharvaris by 225.5% during the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after acquiring an additional 281,829 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Pharvaris in the 2nd quarter valued at about $26,677,000. Seven Fleet Capital Management LP increased its stake in shares of Pharvaris by 472.3% in the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after purchasing an additional 261,355 shares in the last quarter. DV Trading LLC acquired a new position in Pharvaris in the 1st quarter worth about $4,067,000. Finally, Moore Capital Management LP purchased a new position in Pharvaris during the second quarter worth approximately $1,522,000.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.